Answer
Pifeltro (doravirine), combined with other antiretroviral medicines, is indicated for adults and adolescents aged 12 years or older weighing at least 35 kg with HIV-1 infection and no past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
Sources for this answer
- Pifeltro 100 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 14Document updated
Sources checked